Tag: Venous

CX 2024: Dive into the Venous and Lymphatic Podium Firsts

Manj Gohel (Cambridge, UK), member of the Venous Executive Board, parachutes straight into the CX Venous and Lymphatics Controversies Programme to highlight the VenaSeal SPECTRUM...

Venous Summit 2023: Holistic, multidisciplinary approach to venous care is “mandatory”

This advertorial, sponsored by BD, is intended only for readers outside the USA. “A dedicated, holistic venous approach is mandatory—including deep, superficial and pelvic venous...

CX 2023 seeks consensus in “rapidly” progressing venous field

The CX 2023 Venous & Lymphatic programme it set to be a “highlight” of this year’s meeting, CX co-chair and executive board member Erin...

“Value for money is mandatory”—challenging questions on best treatment, cost-effectiveness and...

 Speaking to Venous News at VEITHsymposium 2022 (15–19 November, New York, USA) Armando Mansilha (Porto, Portugal) answers the “challenging question” of how to best...
The Geko device

Sky Medical Technology receives FDA clearance for (W3) geko device

Sky Medical Technology has announced it has achieved further US Food and Drug Administration (FDA) 510(k) clearance to market the new (W3) geko device...

CX returns to in-person format once more in the London spring

Charing Cross (CX) chair Roger Greenhalgh welcomes the vascular community to this year's symposium, due to be held 26–28 April in London, UK, and...

Use of non-medical staff should be considered to address “sorry state”...

 Venous care in the UK is in a “sorry state at the moment”, Zola Mzimba (Derry, UK) tells Venous News. This is in part down...

CLEAR-DVT highlights “real paradigm shift” in treatment of DVT patients

Venous News takes a look back at VIVA 2019 (Vascular InterVentional Advances; 4–7 November, Las Vegas, USA) where Stephen Black (London, UK) and Mitchell Silver (Columbus, USA) discuss the CLEAR-DVT study.  Silver touches...

Telehealth ‘will change the future of venous practice’ post COVID-19

Six venous specialists, Manj Gohel (Cambridge, UK), Ian Franklin (London, UK) Alun Davies (London, UK), Sriram Narayanan (Singapore), Raghu Kolluri (Columbus, USA) and Stephen...

VEITH 2019: Abre venous stent study baseline demographic data presented

This video is only available in selected geographies Stephen Black (London, UK) talks to VEITHtv about how the dedicated venous open-cell nitinol Abre stent (Medtronic)...

Thrombosis is major by-product of infection with COVID-19, but evidence to...

Manj Gohel (Cambridge, UK), one of the editors-in-chief of Venous News, introduces a special COVID-19 video with leading thrombosis and haemostasis experts, including Beverley...

First look at CLOUT registry reveals over 75% of DVT patients...

David J. Dexter, (Sentara Healthcare, Norfolk, VA, USA), principal investigator of the CLOUT registry using the ClotTriever Mechanical Thrombectomy System (Inari Medical) for treatment...

The new Venovo Venous Stent is changing clinical practice

Steven Dubenec (Sydney, Australia) and Gerard O’Sullivan (Galway, Ireland) discuss the impact of dedicated venous stents, in particular the Venovo venous stent (BD, formerly...

Deep venous interventions are an exciting area, but “stark evidence gaps”...

 Venous News arranged a roundtable with Sophie Renton (London, UK), Bruce Campbell (Exeter, UK) and Manj Gohel (Cambridge, UK), who called for more high quality,...

Endovenous laser therapy of saphenous vein reflux using thulium laser with...

In this clinical study the one-year results of the endovenous laser therapy (ELT) application of 1,940nm laser (Vela XL, Boston Scientific) with respect to...

The success of deep venous intervention rests on mid- to long-term...

In this interview, Vascular News speaks to Prakash Saha, King’s College Hospital, London, UK, about the growth of deep venous treatment and how the...

WAVES trial shows 100% vein closure at one month with short...

A post-market evaluation of the VenaSeal closure system (Medtronic) has found that, at one month, 100% of treated veins remained closed, quality of life...

Varithena earns FDA approval for 30-day post-activation shelf life

BTG has announced that the US Food and Drug Administration (FDA) has approved an extension of the post-activation shelf life of Varithena (polidocanol injectable foam)...